Price to Book Value Chart

View Price to Book Value for GIFLF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Price to Book Value Chart
Start Trial

Historical Price to Book Value Data

View and export this data back to 2007. Start Trial.
Date Value
September 18, 2026 1.195
September 17, 2026 1.195
September 16, 2026 1.195
September 15, 2026 1.195
September 14, 2026 1.216
September 11, 2026 1.216
September 10, 2026 1.216
September 09, 2026 1.189
September 08, 2026 1.189
September 04, 2026 1.189
September 03, 2026 1.262
September 02, 2026 1.262
September 01, 2026 1.262
August 31, 2026 1.262
August 28, 2026 1.262
August 27, 2026 1.262
August 26, 2026 1.262
August 25, 2026 1.262
August 24, 2026 1.262
August 21, 2026 1.262
August 20, 2026 1.262
August 19, 2026 1.262
August 18, 2026 1.262
August 17, 2026 1.262
August 14, 2026 1.262
Date Value
August 13, 2026 1.262
August 12, 2026 1.262
August 11, 2026 1.262
August 10, 2026 1.262
August 07, 2026 1.262
August 06, 2026 1.262
August 05, 2026 1.262
August 04, 2026 1.262
August 03, 2026 1.100
July 31, 2026 1.100
July 30, 2026 1.100
July 29, 2026 1.100
July 28, 2026 1.100
July 27, 2026 1.100
July 24, 2026 1.100
July 23, 2026 1.100
July 22, 2026 1.100
July 21, 2026 1.100
July 20, 2026 1.100
July 17, 2026 1.100
July 16, 2026 1.100
July 15, 2026 1.087
July 14, 2026 1.087
July 13, 2026 1.110
July 10, 2026 1.110

Price to Book Ratio Definition

Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.

Read full definition.

Price to Book Value Range, Past 5 Years

View Price to Book Value Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Price to Book Value Benchmarks

View Price to Book Value Benchmarks
Start Trial
Pharma Mar SA 5.72
Oryzon Genomics SA 2.153
Agenus, Inc. --
Amgen, Inc. 17.84
Anika Therapeutics, Inc. 2.029

Price to Book Value Related Metrics